Status:
UNKNOWN
Microbiome Immunotherapy Toxicity and Response Evaluation
Lead Sponsor:
CCTU- Cancer Theme
Collaborating Sponsors:
Microbiotica Ltd
Conditions:
Melanoma
Renal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
Detailed Description
The gastrointestinal microbiome of a healthy individual is comprised of many hundreds of bacteria species and thousands of bacteria strains. The composition of bacteria in an individual's microbiome c...
Eligibility Criteria
Inclusion
- Inclusion Criteria for cancer patients:
- Signed informed consent
- Aged ≥18 years old
- Histological or cytological confirmation of invasive malignancy
- Due to commence palliative, adjuvant or neoadjuvant systemic therapy including an anti-PD-(L)1 antibody +/- anti-CTLA-4 antibody
- Patients with unresectable disease must have radiologically and/or clinically measurable disease, by RECIST version 1.1; target lesions must not have been previously irradiated; baseline tumour assessments must be performed within 45 days prior to starting immune checkpoint inhibitor treatment
- Received no prior immune checkpoint inhibitors (previous treatment with other types of anti-cancer therapy is determined by patient cohort; for patients with unresectable disease, prior adjuvant therapy with immune checkpoint inhibitor(s) is allowed).
- Willing and able to comply with scheduled visits, treatment plans, sample collections and other study procedures
- Exclusion Criteria for cancer patients:
- Other invasive malignancies diagnosed within the last year which are not fully resected, or in complete remission, or for which additional therapy is required
- Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk, or interfere with their ability to comply with the study. Examples may include, but are not limited to:
- Patients with uncontrolled ischaemic heart or other cardiovascular event (e.g. myocardial infarction, new angina, stroke, transient ischaemic attack, or new congestive cardiac failure) within the last 6 months
- Presence of active infection
- Cirrhotic liver disease, known chronic active or acute hepatitis B, or hepatitis C
- Current active, severe, or uncontrolled autoimmune condition, including but not limited to Crohn's disease and ulcerative colitis.
- Women who are pregnant, plan to become pregnant or are lactating during the study period.
- Requirement for non-physiological dose of oral steroids, or regular use of any other immunosuppressive agents; less than 10mg prednisolone or equivalent doses are allowed. Use of inhaled or topical steroids is allowed.
- Household control eligibility requirements:
- Confirmation of suitability to be a household control participant will be determined by completing a self-assessed questionnaire either at home or in clinic.
- Household controls must:
- NOT have had any gastrointestinal infections i.e., parasites, viruses or diarrhoeal episodes during the last 6 months.
- NOT have taken antibiotics for at least 6 months
- NOT have or be recovering from any chronic intestinal disease such as:
- Crohn's disease
- Ulcerative colitis
- Coeliac disease
- Irritable bowel syndrome
- Stomach ulcers
- NOT have a chronic autoimmune disease or significant allergies e.g., multiple sclerosis, asthma requiring regular medication, psoriasis.
- NOT have and NOT be recovering from any form of cancer.
- NOT take proton pump inhibitors, steroids, other non-steroidal anti-inflammatory drugs such as ibuprofen or aspirin.
- NOT had requirement to be hospitalised for treatment of COVID-19
- In addition, household controls must sign informed consent and be aged ≥18 years old.
Exclusion
Key Trial Info
Start Date :
July 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 8 2025
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT04107168
Start Date
July 8 2020
End Date
July 8 2025
Last Update
February 16 2023
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom, BA1 3NG
2
University Hospitals Dorest NHS Foundation Trust
Bournemouth, United Kingdom, BH7 7DW
3
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom, BS2 8ED
4
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom, CB2 0QQ